CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
DOI 10.1055/s-0041-1733733
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Galle, RS Finn, S Qin, M Ikeda, M Ducreux, T-Y Kim, M Kudo, HY Lim, V Breder, P Merle, A Kaseb, D Li, Y-H Feng, W Verret, A Nicholas, L Li, N Ma, AX Zhu, A-L Cheng
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2021
Jahrgang / SeitenJg. 59 · S. e253
Kernaussage aus der Literatur
Abstract-Vorschau
IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
Zitieren
Zitierempfehlung
P Galle, RS Finn, S Qin, M Ikeda, M Ducreux, T-Y Kim, M Kudo, HY Lim, V Breder, P Merle, A Kaseb, D Li, Y-H Feng, W Verret, A Nicholas, L Li, N Ma, AX Zhu, A-L Cheng (2021) IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC). Zeitschrift für Gastroenterologie, 59 (08), e253. https://doi.org/10.1055/s-0041-1733733
Mit CareLit weiterarbeiten